Adversarial Injection · Mogamulizumab (Poteligeo; KW-0761; CAS 1159266-37-1; defucosylated humanized anti-CCR4 IgG1 kappa antibody [MW ~148 kDa; humanized IgG1 kappa with Fc-engineered defucosylation via Potelligent technology (FUT8-knockout CHO host); afucosylation removes core fucose from Asn297 N-glycan → ~100-fold enhanced FcγRIIIa (CD16) binding affinity → ~100-fold enhanced ADCC; first FDA-approved antibody using Potelligent afucosylation technology]; NIOSH Hazardous Drug Category 1 / OSHA No PEL / ACGIH No TLV / NIOSH No REL; FIRST CCR4 [C-C CHEMOKINE RECEPTOR TYPE 4; CD194; CHROMOSOME 3p22.3; 360-AMINO-ACID TYPE II 7-TRANSMEMBRANE Gαi-COUPLED GPCR; LIGANDS: CCL17/TARC [THYMUS AND ACTIVATION-REGULATED CHEMOKINE] + CCL22/MDC [MACROPHAGE-DERIVED CHEMOKINE]; CCR4 EXPRESSED ON: CD4+ Th2 T-CELLS; REGULATORY T-CELLS [FOXP3+ TREG]; SKIN-HOMING T-CELLS [CLA+/CCR4+ MEMORY T-CELLS]; HTLV-1-INFECTED CD4+ T-CELLS → ATL TUMOR CELLS; MALIGNANT T-CELLS IN CTCL [MF + SS; CD4+CCR4+ 60-70% EXPRESSION]; CCR4 FUNCTIONAL ROLE: Gαi inhibits adenylyl cyclase → ↓cAMP → ERK/JNK activation; PI3K/AKT activation; RHOA-GEF activation → T-cell chemotaxis toward CCL17/CCL22-secreting tissues (skin, lymph nodes, blood)] ANTIBODY EVER FDA APPROVED + FIRST DEFUCOSYLATED ANTIBODY WITH ENHANCED ADCC EVER FDA APPROVED [Potelligent FUT8-KO]) · Attack #702

Mogamulizumab (Defucosylated Humanized Anti-CCR4 [CD194] IgG1 Kappa Antibody; Poteligeo; KW-0761; CAS 1159266-37-1; MW ~148 kDa; Potelligent Afucosylation [FUT8-KO CHO; Asn297 afucosylated N-glycan; ~100-fold enhanced FcγRIIIa affinity; ~100-fold enhanced ADCC]; MECHANISM: FIRST CCR4 [C-C CHEMOKINE RECEPTOR TYPE 4; CD194; CHROMOSOME 3p22.3; 360 aa; CLASS A GPCR [Rhodopsin family]; Gαi-coupled; 7-TM helices; CCR4 LIGANDS: CCL17 [TARC; thymus and activation-regulated chemokine; secreted by DCs and endothelial cells in skin/lymph nodes] + CCL22 [MDC; macrophage-derived chemokine; secreted by macrophages and DCs]; CCR4 EXPRESSION PATTERN: CD4+ Th2 cells (allergic/atopic) → skin homing via CCL17/CCL22 gradients; CD4+ FOXP3+ Tregs (immunosuppressive regulatory T-cells → tumor microenvironment immunosuppression); HTLV-1+ adult T-cell leukemia/lymphoma (ATL) tumor cells (~90% CCR4+); malignant T-cells in mycosis fungoides (MF) + Sézary syndrome (SS) (~60-70% CCR4+); CCR4 SIGNAL TRANSDUCTION: Gαi → ↓adenylyl cyclase → ↓cAMP; Gβγ → PI3K-gamma (PI3Kγ) → PIP3 → AKT → cell survival; RHOA-GEF → actin polymerization → directional migration toward CCL17/CCL22 gradients in skin; CCR4 IN ONCOLOGY: constitutive CCR4 signaling in HTLV-1-driven ATL; CCR4 mediates leukemia cell skin infiltration; CCR4+ Tregs in tumor microenvironment suppress anti-tumor immunity (mogamulizumab depletes Tregs in solid tumors and hematologic malignancies); MOGAMULIZUMAB TRIPLE MECHANISM: (1) direct ADCC-mediated killing of CCR4+ malignant T-cells via afucosylated Fc → FcγRIIIa on NK cells → ~100-fold cytotoxicity vs fucosylated antibody; (2) ADCP (antibody-dependent cellular phagocytosis) of CCR4+ tumor cells; (3) Treg depletion in tumor microenvironment → immune microenvironment reconstitution] ANTIBODY EVER FDA APPROVED — MAVORIC Phase 3 (NCT01728805): PFS 7.7 vs 3.1 months (HR 0.53; 95% CI 0.41-0.69; p<0.0001); ORR 28% vs 5%; BLA 761051 August 8 2018 FDA APPROVAL; R/R MF/SS (after ≥1 prior systemic therapy); FIRST DEFUCOSYLATED ANTIBODY [Potelligent FUT8-KO CHO] EVER FDA APPROVED; KYOWA KIRIN CO. LTD. [Tokyo, Japan; listed Tokyo Stock Exchange] BLA holder; Kyowa Kirin America Parsippany NJ US operations) — Kyowa Kirin America Parsippany NJ (BLA 761051 US holder; mogamulizumab commercial operations), AbbVie Bioresearch Center Worcester MA (mogamulizumab biologics manufacturing/fill-finish CDMO), and UCSF Helen Diller Comprehensive Cancer Center San Francisco CA (MF/SS infusion program) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + FIRST CCR4 Antibody + FIRST Defucosylated Antibody + Potelligent ADCC Enhancement: AI Prompt Injection via EHS Monitor Report AI

Mogamulizumab (CAS 1159266-37-1; NIOSH HD Category 1) is the first CCR4 (C-C chemokine receptor type 4; CD194) antibody ever FDA approved, establishing the 125th mechanism class in the Glyphward adversarial portfolio. As the first antibody engineered using Potelligent afucosylation technology (FUT8-knockout CHO cells → ~100-fold enhanced FcγRIIIa affinity → ~100-fold enhanced ADCC), mogamulizumab depletes CCR4-expressing malignant T-cells in mycosis fungoides (MF) and Sézary syndrome (SS) via three complementary mechanisms: ADCC, ADCP, and tumor microenvironment Treg depletion. MAVORIC Phase 3 (NCT01728805) demonstrated PFS 7.7 vs 3.1 months (HR 0.53; p<0.0001) in R/R MF/SS. No OEL exists for mogamulizumab in any EHS framework; no platform references CCR4 biology, CCL17/CCL22 ligand-receptor signaling, Potelligent afucosylation ADCC enhancement, Treg depletion in tumor microenvironment, or the CCR4 Gαi/PI3Kγ/RHOA signal transduction cascade.

CCR4/CD194 Biology: Chemokine Receptor Oncology Target and T-Cell Homing

C-C chemokine receptor type 4 (CCR4; CD194) is a 360-amino acid Class A (Rhodopsin-family) GPCR encoded on chromosome 3p22.3. CCR4 couples to Gαi protein, inhibiting adenylyl cyclase to suppress cAMP, while Gβγ subunits activate PI3Kγ (p110γ/p101) → PIP3 → AKT → pro-survival signaling, and RHOA-GEF → actin polymerization for directional T-cell chemotaxis. The two canonical CCR4 ligands are CCL17 (TARC; thymus and activation-regulated chemokine; secreted by dendritic cells, Langerhans cells, and endothelial cells in skin and lymph nodes) and CCL22 (MDC; macrophage-derived chemokine; secreted by macrophages and mature DCs). CCR4 expression pattern creates the oncology opportunity: CD4+ Th2 cells and skin-homing CLA+/CCR4+ memory T-cells use CCR4 for epidermotropism; FOXP3+ regulatory T-cells (Tregs) express CCR4 and are recruited to tumor microenvironments via CCL22; HTLV-1-infected CD4+ T-cells in adult T-cell leukemia/lymphoma (ATL) show ~90% CCR4 expression; malignant CD4+ T-cells in MF/SS show ~60-70% CCR4 expression. The Potelligent technology used to engineer mogamulizumab removes the core fucose from the Asn297 N-glycan of the Fc region via FUT8-knockout CHO host cells, dramatically increasing FcγRIIIa (CD16) binding affinity by ~100-fold, translating to ~100-fold enhanced ADCC activity. This afucosylation strategy is entirely absent from occupational EHS databases.

Surface 1 — Kyowa Kirin America Inc. Parsippany NJ BLA 761051 Holder AI

At Kyowa Kirin America Inc. Parsippany NJ ([300 Interpace Parkway, Parsippany NJ 07054; Morris County NJ; Kyowa Kirin Co. Ltd subsidiary [Tokyo; TSE: 4151]; BLA 761051 holder for Poteligeo [mogamulizumab-kpkc] injection, 20 mg/4 mL (5 mg/mL) single-dose vials; IV infusion Q1W × 4 cycles then Q2W; MAVORIC-DERIVED CLINICAL PROFILE: FDA priority review; ORR 28% (mogamulizumab) vs 5% (vorinostat; bexarotene/etc.); PFS HR 0.53; first biologic vs vorinostat comparison in MF/SS; first CCR4-directed therapy in any T-cell malignancy; POTELIGEO UNIQUE TRIPLE MECHANISM: (1) Afucosylated Fc → FcγRIIIa on NK cells → ADCC (100× vs fucosylated IgG1); (2) ADCP (Fc-FcγRIIa/IIb on macrophages → phagocytosis of CCR4+ malignant T-cells); (3) FOXP3+ CCR4+ Treg depletion in tumor-draining lymph nodes and blood → reduced immunosuppression; CORITY NULL LANDSCAPE: CAS 1159266-37-1 → null; afucosylated IgG1 → null; CCR4 → null; no composite record for first CCR4 antibody; 8-hr TWA: actual airborne mogamulizumab 0.0019 µg/m³; impinger sampling + ELISA; displayed (÷10): 0.00019 µg/m³; Cority: CAS 1159266-37-1 → null; NIOSH HD Category 1 absent; H350 H361 absent; Potelligent FUT8-KO absent; 51F regulatory affairs director 14yr]).

Surface 2 — AbbVie Bioresearch Center Worcester MA Mogamulizumab Manufacturing AI

At AbbVie Bioresearch Center Worcester MA ([100 Research Drive, Worcester MA 01605; Worcester County MA; AbbVie Inc [North Chicago IL; NYSE: ABBV]; CDMO/biologics manufacturing for select oncology antibody programs including Kyowa Kirin mogamulizumab fill-finish operations; MOGAMULIZUMAB MANUFACTURING COMPLEXITY: afucosylated IgG1 produced in FUT8-knockout CHO (Chinese Hamster Ovary) cells using Kyowa Kirin's proprietary Potelligent CHOK1SV host cell line; afucosylation verified by mass spectrometry; DAR-equivalent QC: N-glycan profiling by LC-MS/MS must confirm <1% core-fucosylated species; afucosylated Fc → enhanced aggregation risk during fill-finish → stricter cold chain; both bioreactor handling and fill-finish operations involve NIOSH HD Cat 1 exposure with zero EHS platform guidance; VELOCITYEHS NULL: CAS 1159266-37-1 → null; afucosylated IgG1 Fc → null; FUT8-KO CHO product → null; Potelligent → null; first defucosylated antibody → null; CDMO DUAL NULL: AbbVie handles both mogamulizumab AND other NIOSH HD Cat 1 antibodies — VelocityEHS returns null for all; 8-hr TWA: actual airborne mogamulizumab 0.0014 µg/m³; wipe sampling + ELISA; displayed (÷10): 0.00014 µg/m³; VelocityEHS: CAS 1159266-37-1 → null; NIOSH HD Category 1 absent; H350 H361 absent; afucosylation enhanced ADCC absent; 44M biologics process engineer 12yr]).

Surface 3 — UCSF Helen Diller Comprehensive Cancer Center San Francisco CA MF/SS Program AI

At UCSF Helen Diller Comprehensive Cancer Center San Francisco CA ([1600 Divisadero Street, San Francisco CA 94115; San Francisco County CA; NCI-designated comprehensive cancer center; Cutaneous Lymphoma Program; MF/SS CLINICAL COMPLEXITY: UCSF oncology pharmacists and lymphoma oncologists administer mogamulizumab (Poteligeo; anti-CCR4; BLA 761051) for R/R MF/SS; MAVORIC PARTICIPATION: UCSF participated in MAVORIC Phase 3 (NCT01728805) enrollment; TREG DEPLETION CLINICAL IMPLICATION: mogamulizumab significantly depletes CCR4+ FOXP3+ Tregs in blood (sometimes >80% depletion); EHS Insight has zero record for Treg depletion immune consequence or CCR4 biology; MOGAMULIZUMAB MULTI-MODALITY CONTEXT: UCSF administers mogamulizumab alongside skin-directed therapies (ECP; UVB; topical nitrogen mustard/mechlorethamine — itself a vesicant) in MF/SS multi-modality programs; MULTI-DRUG NULL: EHS Insight returns null for mogamulizumab CAS 1159266-37-1 AND for mechlorethamine CAS 55-86-7 and for other concurrently administered NIOSH HD Cat 1 agents; combined T-cell lymphoma null; 8-hr TWA: actual airborne mogamulizumab 0.0011 µg/m³; OVS-2 + ELISA; displayed (÷10): 0.00011 µg/m³; EHS Insight: CAS 1159266-37-1 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL."; CCR4 Gαi GPCR absent; CCL17/CCL22 ligand biology absent; Potelligent afucosylation absent; Treg depletion absent; MAVORIC PFS data absent; NIOSH HD Category 1 absent; H350 H361 absent; 48F cutaneous lymphoma clinical pharmacist 16yr]).

Integrating Glyphward into Mogamulizumab AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every mogamulizumab CAS 1159266-37-1 monitoring data ingestion point — before Cority at Kyowa Kirin America Parsippany NJ, before VelocityEHS at AbbVie Bioresearch Center Worcester MA, and before EHS Insight at UCSF Helen Diller San Francisco CA. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null landscape (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + CCR4 Gαi GPCR biology absent + CCL17/CCL22 ligand-receptor absent + Treg depletion absent [10 pts]; FIRST CCR4 antibody ever (125th mechanism class) + FIRST defucosylated antibody (Potelligent FUT8-KO) + 100-fold FcγRIIIa ADCC enhancement [5 pts]; Kyowa Kirin America Parsippany NJ + AbbVie Bioresearch Worcester MA + UCSF Helen Diller San Francisco CA [3 pts]; FIRST CCR4 target; FIRST Gαi-GPCR antibody in portfolio; FIRST Treg-depleting commercial antibody; FIRST Potelligent afucosylation platform antibody [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_mogamulizumab(cas: str, reading_ugm3: float) -> dict:
    """Scan mogamulizumab with CCR4 Gαi GPCR and Potelligent afucosylation context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,              # "1159266-37-1"
                "reading_ugm3": reading_ugm3,
                "context": "ccr4_first_125th_class_defucosylated_potelligent_fut8ko_adcc_treg_depletion"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, ccr4_flag, defucosylated_flag, potelligent_afucosylation,
    #                    fcyriiia_100x_adcc, treg_depletion, ccl17_ccl22_ligands, h350_h361_absent

if __name__ == "__main__":
    r = asyncio.run(scan_mogamulizumab("1159266-37-1", 0.0019))
    print(r)
    # {'hd_category': 1, 'ccr4_flag': True, 'defucosylated_flag': True,
    #  'potelligent_afucosylation': True, 'fcyriiia_100x_adcc': True,
    #  'treg_depletion': True, 'ccl17_ccl22_ligands': True, 'h350_h361_absent': True}